Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-5273

CT26-KRAS-G12C-KI Cell Line

Home » CT26-KRAS-G12C-KI Cell Line

Background of CT26-KRAS-G12C-KI Cell Line

Kirsten rat sarcoma viral oncogene homologue (KRAS) is the best-known oncogene with the highest mutation rate among all cancers and is associated with a series of highly fatal cancers, including pancreatic ductal adenocarcinoma (PDAC), nonsmall-cell lung cancer (NSCLC), and colorectal cancer (CRC). The identification of tumor driver genes and the development of specific inhibitors have revolutionized cancer treatment strategies and clinical outcomes.

Specifications

Catalog Number:
KC-5273
Cell Line Name:
CT26-KRAS-G12C-KI Cell Line
Clone Number
3B1
Host Cell Line:
CT26
Description:
Stable CT26 clone expressing exogenous KRAS gene bearing G12C mutations, No.3B1
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% RPMI1640 + 20% FBS + 10% DMSO
Propagation Medium:
RPMI1640 + 10% FBS
Selection Marker:
NA
Morphology:
Epithelial
Subculture:
Split saturated culture 1:4-1:5 every 1-2 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 24 hours
Mycoplasma Status:
Negative
In Vivo Validation:

Cell Line Generation

CT26-KRAS-G12C-KI-1C1 cell line was generated using the CRISPR method.

Characterization

Figure 1: Characterization of CT26-KRAS-G12C-KI-3B1 cell line stable clone using PCR sequencing.

Figure 2: Characterization of CT26-KRAS-G12C-KI-3B1 cell line stable clone using RT-PCR sequencing.

Figure 3: Characterization of dose-response curves for KRAS inhibitors on CT26 and CT26-KRAS-G12C-KI-3B1 cells.

Cell Resuscitation

  1. Prewarm culture medium (RPMI1640 + 10% FBS) in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:4-1:5 every 1-2 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% RPMI1640 + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage.

References

  1. Lamei Huang, Zhixing Guo, Fang Wang & Liwu Fu. KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy (2021) 6:386 ; https://doi.org/10.1038/s41392-021-00780-4.